Aduro has three complementary vaccine platforms that provide breadth and enable synergistic combinations for developing vaccines for cancer, infectious diseases and biodefense.
Our lead program is a Phase 2 clinical trial of the sequential administration of GVAX Pancreas followed by CRS-207 in patients with metastatic pancreatic cancer. This combination was first shown by Aduro to be synergistic in mouse models, demonstrating enhanced tumor-specific T cell and anti-tumor responses. Because both GVAX Pancreas and CRS-207 target the tumor-associated antigen mesothelin, the sequential administration is a heterologous prime-boost regimen. Listeria is known to be especially effective in this regimen. For more information, please see Clinical Trials.
We are also combining CDNs with GVAX into a new vaccine named STINGVAX and have demonstrated superior efficacy over GVAX alone in animal models. Ultimately, we may combine all three platforms.